AzTrials
AzTrials

COVID-19Phase 3COMMUNITYNCT04590586

Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients

A Phase 3 study testing Apremilast and Lanadelumab in people with COVID-19, run by Amgen at 59 sites in 8 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The primary objective of this study is to evaluate the time to confirmed clinical recovery in participants hospitalized with COVID-19. Candidate agents will be evaluated frequently for efficacy and safety, with candidate agents being added to and/or removed from the study on an ongoing basis, depending on the results… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
COVID-19
What is being tested?
Apremilast and Lanadelumab
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
515 participants
Where
59 sitesin 8 countries
Study dates
24 Nov 2020to 3 Aug 2021
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adults (≥18 years of age) with active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection confirmed by laboratory tests and/or point of care tests (eg, commercial or public health assay, which is approved for emergency use). If no diagnostic test results are available that have been obtained during the previous 72 hours, then a test should be performed as part of the screening assessment.
  • A score of Grade 2 (hospitalized, on invasive mechanical ventilation or ECMO), Grade 3 (hospitalized, on noninvasive ventilation or high-flow oxygen devices), Grade 4 (hospitalized, requiring supplemental oxygen), or Grade 5 (hospitalized, not requiring supplemental oxygen, requiring ongoing medical care [COVID-19 related or otherwise]), as defined by an 8 point ordinal scale.
  • Male participants:
  • A male participant must agree to use contraception during the treatment period and for at least 6 weeks after the last dose of study treatment and refrain from donating sperm during this period.
  • Female participants:
  • A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:
Show all 11Show fewer
  • Not a woman of childbearing potential (WOCBP). OR
  • A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 6 weeks after the last dose of study treatment.
  • Ability to provide informed consent signed by the study participant or legally authorized representative.
  • Ability and willingness to participate in telephone/telemedicine follow-up visits if needed.
  • Zilucoplan only: Antibiotic prophylaxis: all participants must be willing to take antibiotic prophylaxis concomitantly, starting with the first dose of zilucoplan or placebo.

Who cannot join

  • Participant has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the participant (eg, compromise their well-being) or that could prevent, limit, or confound the protocol-specified assessments (eg, participants unable to swallow study medication tablets).
  • Stage 4 severe chronic kidney disease or requiring dialysis.
  • Screening 12-lead electrocardiogram (ECG) with a measurable QTc interval according to Fridericia correction (QTcF) ≥ 500 ms.
  • Anticipated transfer to another hospital that is not a study center within 72 hours.
  • Participants who are currently pregnant or who are not willing to discontinue breastfeeding.
  • Participants participating in another clinical study of an investigational medicinal product or other unapproved (or investigational) treatment for COVID-19.
Show all 16Show fewer
  • Active tuberculosis or a history of incompletely treated tuberculosis.
  • Active, uncontrolled systemic bacterial or fungal infection(s).
  • Apremilast only: Current treatment with apremilast, or another agent of similar mechanism of action, for any indication within 1 week prior to first dose of investigational product.
  • Apremilast only: Concurrent use at screening or randomization of cytochrome P450 (CYP)3A inducers (eg, rifampin, phenobarbital, carbamazepine) within 1 week prior to first dose of investigational product.
  • Apremilast only: Known hypersensitivity to apremilast or any excipients in formulation.
  • Lanadelumab only: Known or suspected hypersensitivity to lanadelumab or any of its excipients.
  • Lanadelumab only: Previous (within 3 months prior to baseline) or current use of immunomodulators (eg, methotrexate, azathioprine, 6-mercaptopurine, tumor necrosis factor [TNF] α inhibitor, Janus kinase [JAK] inhibitor, alpha-integrin inhibitor).
  • Lanadelumab only: Known or suspected venous thromboembolism.
  • Lanadelumab only: Previous (within 3 months [or 5 half-lives, whichever is greater] of screening) or current use of plasma kallikrein (pKal) inhibitor or bradykinin receptor blocker.
  • Zilucoplan only: Participants with unresolved or suspected infection with Neisseria meningitidis or a past history of N. meningitidis (eg, in a complement-deficient patient).

Trial locations and contacts

59 sites in 8 countries.

59 sites in 8 countries

United States21 sites
  • Pinnacle Research Group LLC

    Anniston, Alabama, 36207

  • Grady Health System

    Atlanta, Georgia, 30303

  • Good Samaritan Hospital

    Bakersfield, California, 93309

  • Great Lakes Clinical Trials

    Chicago, Illinois, 60640

  • Sharp Chula Vista Medical Center

    Chula Vista, California, 91910

  • Harper University Hospital

    Detroit, Michigan, 48201-2018

  • Sinai Grace Hospital

    Detroit, Michigan, 48235

  • El Centro Regional Medical Center

    El Centro, California, 92243

  • Medical City Ft. Worth

    Fort Worth, Texas, 76104

  • UF Health Shands Hospital

    Gainesville, Florida, 32610

  • University of Texas Health Science Center at Houston

    Houston, Texas, 77030

  • The University of Iowa

    Iowa City, Iowa, 52242

  • Memorial Hospital Jacksonville

    Jacksonville, Florida, 32216

  • University of Tennessee Health Sciences Center

    Memphis, Tennessee, 38103

  • University of California Irvine Medical Center

    Orange, California, 92868

  • Riverside Community Hospital

    Riverside, California, 92501-4135

  • Detroit Receiving Hospital

    Royal Oak, Michigan, 48073

  • University of California Davis Health System

    Sacramento, California, 95817

  • Texoma Medical Center

    Sherman, Texas, 75090

  • National Institute of Clinical Research

    South El Monte, California, 91733

  • MultiCare Health System Institute for Research and Innovation

    Tacoma, Washington, 98405

Other trials in United States

South Africa9 sites
  • Tread Research

    Cape Town, Western Cape, 7500

  • Tiervlei Trial Centre

    Cape Town, Western Cape, 7530

  • 2 Military Hospital Internal Medicine

    Cape Town, Western Cape, 7800

  • Johese Clinical Research: Unitas

    Centurion, Gauteng, 0157

  • Drs Sarvan and Moodley

    Durban, KwaZulu-Natal, 4320

  • MERC SiReN

    Johannesburg, Gauteng, 2193

  • Nelson Mandela Academic Clinical Research Unit (NeMACRU)

    Mthatha, Eastern Cape, 5100

  • Dr JM Engelbrecht Trial Site

    Somerset West, Western Cape, 7130

  • Clinical Projects Research SA (PTY) LTD

    Worcester, Western Cape, 6850

Other trials in South Africa

Russia7 sites
  • TSBIH "Krasnoyarsk Interdistrict Clinical Hospital of Emergency Medical Care n.a. N.S. Karpovich

    Krasnoyarsk, 660062

  • SBIH of Moscow "Infectious Clinical Hospital # 1 of Department of Healthcare of Moscow"

    Moscow, 125367

  • SPb SBIH "Alexandrovskaya City Hospital"

    Saint Petersburg, 193312

  • St-George Hospital

    Saint Petersburg, 194354

  • SPb SBIH "Nikolaevskaya Hospital"

    Saint Petersburg, 198510

  • SPb SBIH "City Pokrovskaya Hospital"

    Saint Petersburg, 199106

  • SPb SBIH "City Hospital # 40 of Kurortnyi region"

    Sestroretsk, 197706

Other trials in Russia

Brazil6 sites
  • Santa Casa de Misericórdia de Belo Horizonte

    Belo Horizonte, Minas Gerais, 30150-221

  • UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu

    Botucatu, São Paulo, 18618-970

  • Chronos Pesquisa Clinica

    Brasília, Federal District, 72.145-450

  • HC-UFG - Hospital das Clínicas da Universidade Federal de Goiás

    Goiânia, Goiás, 74605-020

  • Hospital de Clínicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, 90035-903

  • Praxis Pesquisa Médica

    Santo André, São Paulo, 09090-790

Other trials in Brazil

Ukraine6 sites
  • Communal Noncommercial Profit "Clinical City Hospital 16 of Dnipro Regional Council"

    Dnipro, 49069

  • CNE of Kharkov RC Reg Cl Infectious Hospital

    Kharkiv, 61096

  • Communal Non-Commercial Medical Enterprise "O.T.Bohayevskyi Kremenchuk City Hospital #1"

    Kremenchuk, 39623

  • City Clinical infectious Hospital

    Odesa, 65026

  • Municipal Non-Profit Enterprise Central City Hospital Of Rivne City Council

    Rivne, 33017

  • CCH #1 Vinnytsia M.I.Pyrogov NMU Ch of Infectious Diseases

    Vinnytsia, 21029

Other trials in Ukraine

Argentina5 sites
  • Hospital General de Agudos Dr. J. M. Ramos Mejia

    Ciudad Autonoma Buenos Aires, C1221ADC

  • Hospital General de Agudos Dr. Ignacio Pirovano

    Ciudad Autonoma Buenos Aires, C1430BKC

  • Clinica Adventista Belgrano

    Ciudad Autonoma Buenos Aires, C1430EGF

  • Hospital San Juan de Dios

    Ramos Mejía, Buenos Aires, 1704

  • Hospital Italiano de Rosario

    Rosario, 2000

Other trials in Argentina

Mexico4 sites
  • Hospital Civil de Culiacan

    Culiacán, Sinaloa, 80030

  • Hospital Civil de Guadalajara Dr. Juan I. Menchaca

    Guadalajara, Jalisco, 44340

  • Universidad Autonoma de Nuevo Leon, Hospital Universitario Dr. Jose Eleuterio Gonzalez

    Monterrey, Nuevo León, 64460

  • Hospital General de Tijuana

    Tijuana, Baja California Norte, 22000

Other trials in Mexico

Chile1 site
  • Hospital Base Osorno

    Osorno, 5290000

Other trials in Chile

About this study

Official title: Industry Alliance Platform Trial to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients

The primary objective of this study is to evaluate the time to confirmed clinical recovery in participants hospitalized with COVID-19. Candidate agents will be evaluated frequently for efficacy and safety, with candidate agents being added to and/or removed from the study on an ongoing basis, depending on the results of their evaluation.

Read the detailed description

This adaptive, randomized, placebo-controlled platform study is designed to rapidly assess multiple candidate agents as treatments for COVID-19 in hospitalized patients. Candidate agents will be evaluated frequently (through ongoing monitoring) for futility and safety, with candidate agents being added to and/or removed from the study on an ongoing basis, depending on the results of their evaluation.

For inclusion, participants will need to be hospitalized with a clinical status of Grade 2 to Grade 5, as defined by the following Clinical Severity Status 8-Point Ordinal Scale:

  1. Death
  2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
  3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices
  4. Hospitalized, requiring supplemental oxygen
  5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)
  6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care
  7. Not hospitalized, limitation on activities and/or requiring home oxygen
  8. Not hospitalized, no limitations on activities

Participants will be randomized equally to either the candidate agent plus standard of care (SoC) or placebo plus SoC in a double-blind fashion. Participants who are randomized to placebo plus SoC will subsequently be randomized equally to a matching placebo corresponding to an available agent whose sub-protocol the patient qualified for (ie, a 2-stage randomization). Each participant in the placebo plus SoC group will only receive one type of placebo. Randomization will be stratified by baseline clinical severity of 2 on the 8-point ordinal scale (yes/no) and remdesivir use at baseline (yes/no).

The study will evaluate each candidate agent separately as an add-on to the SoC to assess safety and efficacy. The comparator group for a candidate agent will include participants randomized to the placebo arm of any sub-protocol according to the following conditions:

  • Apremilast sub-protocol: participants who were enrolled concurrently to apremilast and who would have been eligible for the apremilast sub-protocol.
  • Lanadelumab sub-protocol: at a site where at least one participant was randomized to either lanadelumab active or placebo arms.
  • Zilucoplan sub-protocol: at a site where at least one participant was randomized to either the zilucoplan active or placebo arms.
Conditions
COVID-19
Being tested
Standard of care, Apremilast, Apremilast placebo, Lanadelumab, Lanadelumab placebo
Keywords
SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2
Medical subject headings
COVID-19

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Standard of careDrug

    Standard of care (SoC) treatment for COVID-19 infection in line with institutional practice. The SoC may change as new information becomes available about treating COVID-19.

  • ApremilastDrug

    Also called Otezla

    Apremilast administered orally as a tablet.

  • Apremilast placeboDrug

    Matching apremilast placebo administered orally as a tablet.

  • LanadelumabDrug

    Also called TAKHZYRO™, TAK-743

    Lanadelumab administered as an intravenous (IV) infusion.

  • Lanadelumab placeboDrug

    Matching lanadelumab placebo (normal saline) administered as an intravenous (IV) infusion.

  • ZilucoplanDrug

    Zilucoplan administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.

  • Zilucoplan placeboDrug

    Matching zilucoplan placebo administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.

Study groups in NCT04590586
Study groupRoleWhat they receive
Apremilast + Standard of CareExperimentalParticipants will be randomized to receive 30 mg apremilast orally twice a day (BID) in addition to standard of care treatment for 14 days or until hospital discharge, death, or discontinuation of investigational product, whichever occurred first.
Receives: Drug: Standard of care; Drug: Apremilast
Apremilast Placebo + Standard of CarePlacebo comparatorParticipants will be randomized to receive matching placebo to apremilast orally twice a day in addition to standard of care treatment for 14 days or until hospital discharge, death, or discontinuation of investigational product, whichever occurred first.
Receives: Drug: Standard of care; Drug: Apremilast placebo
Lanadelumab + Standard of CareExperimentalParticipants will be randomized to receive lanadelumab 300 mg by intravenous infusion on Day 1, and a second dose administered on Day 4 in addition to standard of care.
Receives: Drug: Standard of care; Drug: Lanadelumab
Lanadelumab Placebo + Standard of CarePlacebo comparatorParticipants will be randomized to receive placebo to lanadelumab by intravenous infusion on Day 1, and a second dose administered on Day 4 in addition to standard of care.
Receives: Drug: Standard of care; Drug: Lanadelumab placebo
Zilucoplan + Standard of CareExperimentalParticipants will be randomized to receive 32.4 mg zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment in addition to standard of care.
Receives: Drug: Standard of care; Drug: Zilucoplan
Zilucoplan Placebo + Standard of CarePlacebo comparatorParticipants will be randomized to receive placebo to zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment in addition to standard of care.
Receives: Drug: Standard of care; Drug: Zilucoplan placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Lanadelumab Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29

    Confirmed clinical recovery means the participant is fit for discharge from hospital, defined by achieving a score of 6 (hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care), 7 (not hospitalized, limitation on activities and/or requiring home oxygen), or 8 (not hospitalized, no limitations on activities) on the clinical severity status 8-point ordinal scale, without being re-hospitalized prior to Day 29.

    The Kaplan-Meier estimate of the time to confirmed clinical recovery through Day 29, without re-hospitalization through Day 29, was calculated from Study Day 1 to the earliest date on which the participant had a score of 6, 7, or 8 up to Day 29. Participants who never reached a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale before or on Day 29 were censored at Day 29. Participants who discontinued from the study before or on Day 29 were censored at time of discontinuation from study.

    Measured: Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29

  2. Apremilast Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29

    Confirmed clinical recovery means the participant is fit for discharge from hospital, defined by achieving a score of 6 (hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care), 7 (not hospitalized, limitation on activities and/or requiring home oxygen), or 8 (not hospitalized, no limitations on activities) on the clinical severity status 8-point ordinal scale, without being re-hospitalized prior to Day 29.

    The Kaplan-Meier estimate of the time to confirmed clinical recovery through Day 29, without re-hospitalization through Day 29, was calculated from Study Day 1 to the earliest date on which the participant had a score of 6, 7, or 8 up to Day 29. Participants who never reached a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale before or on Day 29 were censored at Day 29. Participants who discontinued from the study before or on Day 29 were censored at time of discontinuation from study.

    Measured: Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29

  3. Zilucoplan Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29

    Confirmed clinical recovery means the participant is fit for discharge from hospital, defined by achieving a score of 6 (hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care), 7 (not hospitalized, limitation on activities and/or requiring home oxygen), or 8 (not hospitalized, no limitations on activities) on the clinical severity status 8-point ordinal scale, without being re-hospitalized prior to Day 29.

    The Kaplan-Meier estimate of the time to confirmed clinical recovery through Day 29, without re-hospitalization through Day 29, was calculated from Study Day 1 to the earliest date on which the participant had a score of 6, 7, or 8 up to Day 29. Participants who never reached a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale before or on Day 29 were censored at Day 29. Participants who discontinued from the study before or on Day 29 were censored at time of discontinuation from study.

    Measured: Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29

Secondary outcomes (30)
  1. Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29

    Oxygen-free recovery at Day 29 is defined as being alive, discharged, and not receiving supplemental oxygen at Day 29. Participants who reached a score of 7 on the ordinal scale for clinical severity who were discharged to hospice care before or on Day 29 were considered as not discharged at Day 29. Participants with a missing oxygen-free recovery status at Day 29 were considered as not having an oxygen-free recovery.

    Measured: Day 29

  2. Lanadelumab Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29

    Fit for discharge is defined as achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with an ordinal scale score of 7 must not have been discharged to hospice care to be considered as fit for discharge. Participants with a missing clinical severity score at Day 29 were considered as not having met the event at Day 29.

    The clinical severity status 8-point ordinal scale scores are:

    1. Death
    2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
    3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices
    4. Hospitalized, requiring supplemental oxygen
    5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)
    6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care
    7. Not hospitalized, limitation on activities and/or requiring home oxygen
    8. Not hospitalized, no limitations on activities

    Measured: Baseline (Day 1) and Day 29

  3. Lanadelumab Sub-protocol: Percentage of Participants Who Died Before or on Day 29

    All-cause mortality is death due to any cause. Participants with an unknown alive/death status on Day 29 were considered alive for this analysis, with the exception of patients with a score of 7 who were discharged to hospice care before or on Day 29.

    Measured: Day 1 to Day 29

  4. Lanadelumab Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29

    The clinical severity status 8-point ordinal scale scores are:

    1. Death
    2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
    3. Hospitalized, on noninvasive ventilation or high flow oxygen devices
    4. Hospitalized, requiring supplemental oxygen
    5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)
    6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care
    7. Not hospitalized, limitation on activities and/or requiring home oxygen
    8. Not hospitalized, no limitations on activities

    Participants with a score of 7 who were discharged to hospice care are counted with participants with a score of 1 (death) for this endpoint.

    Measured: Day 8, Day 15, and Day 29

  5. Lanadelumab Sub-protocol: Worst Post-Baseline Score on Clinical Severity Status 8-point Ordinal Scale From Baseline to Day 29

    The worst post-baseline score (lower scores are worse) through Day 29 in the clinical severity status 8-point ordinal scale, derived from all scores recorded after baseline up to and including Day 29. Participants with a score of 7 discharged to hospice care are considered as having a score of 1 (death) instead of a score of 7 for this endpoint.

    The clinical severity status 8-point ordinal scale scores are:

    1. Death
    2. Hospitalized, on invasive mechanical ventilation or ECMO
    3. Hospitalized, on noninvasive ventilation or high flow oxygen devices
    4. Hospitalized, requiring supplemental oxygen
    5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)
    6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care
    7. Not hospitalized, limitation on activities and/or requiring home oxygen
    8. Not hospitalized, no limitations on activities

    Measured: Day 2 to Day 29

  6. Lanadelumab Sub-protocol: Number of Intensive Care Unit (ICU) Days From Day 1 Through Day 29

    Number of ICU days is the sum of the duration of any episode of ICU admission between Day 1 and Day 29, both inclusive. The number of ICU days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30 (worst possible outcome).

    Measured: Day 1 to Day 29

  7. Lanadelumab Sub-protocol: Number of Invasive Mechanical Ventilator Days From Day 1 Through Day 29

    Number of invasive mechanical ventilator days is the sum of the duration of any episode of invasive mechanical ventilator admission between Day 1 and Day 29, both inclusive. The number of invasive mechanical ventilator days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30.

    Measured: Day 1 to Day 29

  8. Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Clinical Recovery by Days 8, 15, and 29

    Clinical recovery is defined as being fit for discharge, i.e., the achievement of a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who discontinued the study on or before Days 8, 15, or 29 or with a missing clinical recovery status were considered as not having clinical recovery at each respective time point.

    Clinical severity status 8-point ordinal scale:

    1. Death
    2. Hospitalized, on invasive mechanical ventilation or ECMO
    3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices
    4. Hospitalized, requiring supplemental oxygen
    5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care
    6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care
    7. Not hospitalized, limitation on activities and/or requiring home oxygen
    8. Not hospitalized, no limitations on activities

    Measured: Day 8, Day 15, and Day 29

  9. Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery

    Sustained clinical recovery is defined as being fit for discharge (achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale) by Day 29, without re-hospitalization by Day 60. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who died or discontinued from study or with a missing clinical recovery status at Day 60 were not considered having sustained clinical recovery.

    Clinical severity status 8-point ordinal scale:

    1. Death
    2. Hospitalized, on invasive mechanical ventilation or ECMO
    3. Hospitalized, on noninvasive ventilation or high flow oxygen devices
    4. Hospitalized, requiring supplemental oxygen
    5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care
    6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care
    7. Not hospitalized, limitation on activities and/or requiring home oxygen
    8. Not hospitalized, no limitations on activities

    Measured: Day 60

  10. Lanadelumab Sub-protocol: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to study treatment. A TEAE is an AE that occurs after the first dose of study drug. A Serious AE is any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, resulted in persistent disability/incapacity, a congenital anomaly/birth defect, or an important medical event that may jeopardize the patient or require intervention to prevent an outcome listed above.

    The Investigator assessed the intensity of each AE according to the Common Terminology Criteria for Adverse Events (CTCAE):

    • Grade 1 Mild; asymptomatic or mild symptoms;
    • Grade 2 Moderate; minimal, local or noninvasive intervention indicated;
    • Grade 3 Severe or medically significant, not immediately life-threatening;
    • Grade 4 Life-threatening; urgent intervention indicated;
    • Grade 5 Death due to AE.

    Measured: From first dose of study drug to end of study (Day 60)

  11. Apremilast Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29

    Oxygen-free recovery at Day 29 is defined as being alive, discharged, and not receiving supplemental oxygen at Day 29. Participants who reached a score of 7 on the ordinal scale for clinical severity who were discharged to hospice care before or on Day 29 were considered as not discharged at Day 29. Participants with a missing oxygen-free recovery status at Day 29 were considered as not having an oxygen-free recovery.

    Measured: Day 29

  12. Apremilast Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29

    Fit for discharge is defined as achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with an ordinal scale score of 7 must not have been discharged to hospice care to be considered as fit for discharge. Participants with a missing clinical severity score at Day 29 were considered as not having met the event at Day 29.

    The clinical severity status 8-point ordinal scale scores are:

    1. Death
    2. Hospitalized, on invasive mechanical ventilation or ECMO
    3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices
    4. Hospitalized, requiring supplemental oxygen
    5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)
    6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care
    7. Not hospitalized, limitation on activities and/or requiring home oxygen
    8. Not hospitalized, no limitations on activities

    Measured: Baseline (Day 1) and Day 29

  13. Apremilast Sub-protocol: Percentage of Participants Who Died Before or on Day 29

    All-cause mortality is death due to any cause. Participants with an unknown alive/death status on Day 29 were considered alive for this analysis, with the exception of patients with a score of 7 who were discharged to hospice care before or on Day 29.

    Measured: Day 1 to Day 29

  14. Apremilast Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29

    The clinical severity status 8-point ordinal scale scores are:

    1. Death
    2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
    3. Hospitalized, on noninvasive ventilation or high flow oxygen devices
    4. Hospitalized, requiring supplemental oxygen
    5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)
    6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care
    7. Not hospitalized, limitation on activities and/or requiring home oxygen
    8. Not hospitalized, no limitations on activities

    Participants with a score of 7 who were discharged to hospice care are counted with participants with a score of 1 (death) for this endpoint.

    Measured: Day 8, Day 15, and Day 29

  15. Apremilast Sub-protocol: Worst Post-Baseline Score on Clinical Severity Status 8-Point Ordinal Scale From Baseline to Day 29

    The worst post-baseline score (lower scores are worse) through Day 29 in the clinical severity status 8-point ordinal scale, derived from all scores recorded after baseline up to and including Day 29. Participants with a score of 7 discharged to hospice care are considered as having a score of 1 (death) instead of a score of 7 for this endpoint.

    The clinical severity status 8-point ordinal scale scores are:

    1. Death
    2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
    3. Hospitalized, on noninvasive ventilation or high flow oxygen devices
    4. Hospitalized, requiring supplemental oxygen
    5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)
    6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care
    7. Not hospitalized, limitation on activities and/or requiring home oxygen
    8. Not hospitalized, no limitations on activities

    Measured: Day 2 to Day 29

  16. Apremilast Sub-protocol: Number of Intensive Care Unit (ICU) Days From Day 1 Through Day 29

    Number of ICU days is the sum of the duration of any episode of ICU admission between Day 1 and Day 29, both inclusive. The number of ICU days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30 (worst possible outcome).

    Measured: Day 1 to Day 29

  17. Apremilast Sub-protocol: Number of Invasive Mechanical Ventilator Days From Day 1 Through Day 29

    Number of invasive mechanical ventilator days is the sum of the duration of any episode of invasive mechanical ventilator admission between Day 1 and Day 29, both inclusive. The number of invasive mechanical ventilator days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30.

    Measured: Day 1 to Day 29

  18. Apremilast Sub-protocol: Percentage of Participants Who Achieved Clinical Recovery at Days 8, 15, and 29

    Clinical recovery is defined as being fit for discharge, i.e., the achievement of a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who discontinued the study on or before Days 8, 15, or 29 or with a missing clinical recovery status were considered as not having clinical recovery at each respective time point.

    Clinical severity status 8-point ordinal scale:

    1. Death
    2. Hospitalized, on invasive mechanical ventilation or ECMO
    3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices
    4. Hospitalized, requiring supplemental oxygen
    5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care
    6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care
    7. Not hospitalized, limitation on activities and/or requiring home oxygen
    8. Not hospitalized, no limitations on activities

    Measured: Day 8, Day 15, and Day 29

  19. Apremilast Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery

    Sustained clinical recovery is defined as being fit for discharge (achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale) by Day 29, without re-hospitalization by Day 60. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who died or discontinued from study or with a missing clinical recovery status at Day 60 were not considered having sustained clinical recovery.

    Clinical severity status 8-point ordinal scale:

    1. Death
    2. Hospitalized, on invasive mechanical ventilation or ECMO
    3. Hospitalized, on noninvasive ventilation or high flow oxygen devices
    4. Hospitalized, requiring supplemental oxygen
    5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care
    6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care
    7. Not hospitalized, limitation on activities and/or requiring home oxygen
    8. Not hospitalized, no limitations on activities

    Measured: Day 60

  20. Apremilast Sub-protocol: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to study treatment. A TEAE is an AE that occurs after the first dose of study drug. A serious AE is any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, resulted in persistent disability/incapacity, a congenital anomaly/birth defect, or an important medical event that may jeopardize the patient or require intervention to prevent an outcome listed above.

    The Investigator assessed the intensity of each AE according to the CTCAE grades:

    • Grade 1 Mild; asymptomatic or mild symptoms;
    • Grade 2 Moderate; minimal, local or noninvasive intervention indicated;
    • Grade 3 Severe or medically significant, not immediately life-threatening;
    • Grade 4 Life-threatening; urgent intervention indicated;
    • Grade 5 Death due to AE.

    Measured: From first dose of study drug to end of study (Day 60)

  21. Zilucoplan Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29

    Oxygen-free recovery at Day 29 is defined as being alive, discharged, and not receiving supplemental oxygen at Day 29. Participants who reached a score of 7 on the ordinal scale for clinical severity who were discharged to hospice care before or on Day 29 were considered as not discharged at Day 29. Participants with a missing oxygen-free recovery status at Day 29 were considered as not having an oxygen-free recovery.

    Measured: Day 29

  22. Zilucoplan Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29

    Fit for discharge is defined as achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with an ordinal scale score of 7 must not have been discharged to hospice care to be considered as fit for discharge. Participants with a missing clinical severity score at Day 29 were considered as not having met the event at Day 29.

    The clinical severity status 8-point ordinal scale scores are:

    1. Death
    2. Hospitalized, on invasive mechanical ventilation or ECMO
    3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices
    4. Hospitalized, requiring supplemental oxygen
    5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)
    6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care
    7. Not hospitalized, limitation on activities and/or requiring home oxygen
    8. Not hospitalized, no limitations on activities

    Measured: Baseline (Day 1) and Day 29

  23. Zilucoplan Sub-protocol: Percentage of Participants Who Died Before or on Day 29

    All-cause mortality is death due to any cause. Participants with an unknown alive/death status on Day 29 were considered alive for this analysis, with the exception of patients with a score of 7 who were discharged to hospice care before or on Day 29.

    Measured: Day 1 to Day 29

  24. Zilucoplan Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29

    The clinical severity status 8-point ordinal scale scores are:

    1. Death
    2. Hospitalized, on invasive mechanical ventilation or ECMO
    3. Hospitalized, on noninvasive ventilation or high flow oxygen devices
    4. Hospitalized, requiring supplemental oxygen
    5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)
    6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care
    7. Not hospitalized, limitation on activities and/or requiring home oxygen
    8. Not hospitalized, no limitations on activities

    Participants with a score of 7 who were discharged to hospice care are counted with participants with a score of 1 (death) for this endpoint.

    Measured: Day 8, Day 15, and Day 29

  25. Zilucoplan Sub-protocol: Worst Post-Baseline Score on Clinical Severity Status 8-Point Ordinal Scale From Baseline to Day 29

    The worst post-baseline score (lower scores are worse) through Day 29 in the clinical severity status 8-point ordinal scale scores, derived from all scores recorded after baseline up to and including Day 29. Participants with a score of 7 discharged to hospice care were considered as having a score of 1 (death) instead of a score of 7 for this endpoint.

    The clinical severity status 8-point ordinal scale scores scores are:

    1. Death
    2. Hospitalized, on invasive mechanical ventilation or ECMO
    3. Hospitalized, on noninvasive ventilation or high flow oxygen devices
    4. Hospitalized, requiring supplemental oxygen
    5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)
    6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care
    7. Not hospitalized, limitation on activities and/or requiring home oxygen
    8. Not hospitalized, no limitations on activities

    Measured: Day 2 to Day 29

  26. Zilucoplan Sub-protocol: Number of Intensive Care Unit (ICU) Days From Day 1 Through Day 29

    Number of ICU days is the sum of the duration of any episode of ICU admission between Day 1 and Day 29, both inclusive. The number of ICU days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30 (worst possible outcome).

    Measured: Day 1 to Day 29

  27. Zilucoplan Sub-protocol: Number of Invasive Mechanical Ventilator Days From Day 1 Through Day 29

    Number of invasive mechanical ventilator days is the sum of the duration of any episode of invasive mechanical ventilator admission between Day 1 and Day 29, both inclusive. The number of invasive mechanical ventilator days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30.

    Measured: Day 1 to Day 29

  28. Zilucoplan Sub-protocol: Percentage of Participants Who Achieved Clinical Recovery by Days 8, 15, and 29

    Clinical recovery is defined as being fit for discharge, i.e., the achievement of a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who discontinued the study on or before Days 8, 15, or 29 or with a missing clinical recovery status were considered as not having clinical recovery at each respective time point.

    Clinical severity status 8-point ordinal scale:

    1. Death
    2. Hospitalized, on invasive mechanical ventilation or ECMO
    3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices
    4. Hospitalized, requiring supplemental oxygen
    5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care
    6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care
    7. Not hospitalized, limitation on activities and/or requiring home oxygen
    8. Not hospitalized, no limitations on activities

    Measured: Day 8, Day 15, and Day 29

  29. Zilucoplan Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery

    Sustained clinical recovery is defined as being fit for discharge (achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale) by Day 29, without re-hospitalization by Day 60. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who died or discontinued from study or with a missing clinical recovery status at Day 60 were not considered having sustained clinical recovery.

    Clinical severity status 8-point ordinal scale:

    1. Death
    2. Hospitalized, on invasive mechanical ventilation or ECMO
    3. Hospitalized, on noninvasive ventilation or high flow oxygen devices
    4. Hospitalized, requiring supplemental oxygen
    5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care
    6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care
    7. Not hospitalized, limitation on activities and/or requiring home oxygen
    8. Not hospitalized, no limitations on activities

    Measured: Day 60

  30. Zilucoplan Sub-protocol: Number of Participants With Treatment-emergent Adverse Events

    An adverse event is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to study treatment. A TEAE is an AE that occurs after the first dose of study drug. A serious AE is any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, resulted in persistent disability/incapacity, a congenital anomaly/birth defect, or an important medical event that may jeopardize the patient or require intervention to prevent an outcome listed above.

    The Investigator assessed the intensity of each AE according to the CTCAE grades:

    • Grade 1 Mild; asymptomatic or mild symptoms;
    • Grade 2 Moderate; minimal, local or noninvasive intervention indicated;
    • Grade 3 Severe or medically significant, not immediately life-threatening;
    • Grade 4 Life-threatening; urgent intervention indicated;
    • Grade 5 Death due to AE.

    Measured: From first dose of study drug to end of study (Day 60)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Oct 2020
  2. Study start24 Nov 2020
  3. Primary completion3 Aug 2021
  4. Study completion3 Aug 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
515 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04590586
Sponsor's protocol ID
COV-01
Acronym
COMMUNITY
Status last verified
Jun 2022
First submitted
14 Oct 2020
Last updated
29 Jun 2022
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Publications

  • Hu X, Setiadi AF, Detalle L, Sexton D, Finkelman RD, Teixeira Dos Santos MC, Burns CE, Notari KH, Lalla M, Yeung D, Charuworn P. Evaluation of Potential Prognostic Biomarkers for Identifying Adults Hospitalised with COVID-19 at Increased Risk of Adverse Clinical Outcomes. Adv Ther. 2026 Oct 25. doi: 10.1007/s12325-026-03798-8. Online ahead of print.

    PubMed 42928084
  • Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.

    PubMed 34473343

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Apremilast and Lanadelumab in people with COVID-19, run by Amgen at 59 sites in 8 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 Jun 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 59 sites in United States, South Africa, Russia, Brazil, Ukraine and 3 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 29 Jun 2022). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Lanadelumab Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29 (time frame: Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04590586, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jun 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in